Top Japan lab dismisses ground-breaking stem cell study

Image
AFP Tokyo
Last Updated : Dec 26 2014 | 1:40 PM IST
Japan's top research institute today hammered the final nail in the coffin of what was once billed as a ground-breaking stem cell study, dismissing it as flawed and saying the work could have been fabricated.
The revelations come a week after a young researcher at the centre of the scandal, which has rocked the country's scientific establishment, said she would resign after failing to reproduce the successful conversion of an adult cell into a stem cell-like state, known as "STAP" cells.
The failure marked a stunning fall from grace for 31-year-old Haruko Obokata, whose co-researcher committed suicide amid the embarrassing scandal that prompted respected science journal Nature to retract an article detailing the research.
The government-backed Riken institute, which sponsored the study, today said embryonic stem cells had been added in the process of the research, hammering Obokata's contention that she had found an easier way to generate new stem cells in the lab.
"But we can't conclude whether the mixing was done on purpose or by mistake nor can we conclude who did it," probe team chief Isao Katsura, head of the National Institute of Genetics, told a news briefing in Tokyo.
In January, Riken trumpeted Obokata's simple method to re-programme adult cells to work like stem cells.
The study was top news in Japan, where the photogenic Obokata, a Harvard-trained scientist, became a phenomenon.
But media attention soon grew into scepticism as doubts emerged about Obokata's papers on Stimulus-Triggered Acquisition of Pluripotency (STAP).
Mistakes were discovered in some data published in two papers, photograph captions were found to be misleading, and the work itself could not be repeated by other scientists.
The head of the probe team, which was made up of scientists outside the institute and lawyers, today said the committee interviewed Obokata three times.
"During the last of our interviews we told her that we had enough evidence to show the mixing-in (of embryonic stem cells)," Katsura said.
"Then, before us asking anything, Ms.Obokata said 'I've never mixed them.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 26 2014 | 1:40 PM IST

Next Story